Manufacturer of Controlled Substances Notice of Application, 10680 [05-4222]

Download as PDF 10680 Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 23, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4222 Filed 3–3–05; 8:45 am] Dated: February 22, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4203 Filed 3–3–05; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P Pursuant to 21 U.S.C. 958(1), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(b) authorizing the importation of such substances, provide manufacturers holding registrations for the bulk manufacture of the substances an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on December 9, 2004, Lipomed Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances: Drug Enforcement Administration Importation of Controlled Substances; Notice of Application DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Application Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 9, 2004, Lin Zhi International Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedule II. Drug Schedule Oxycodone (9143) ........................ Hydrocodone (9193) ..................... II II The company plans to manufacture the listed controlled substances in bulk for use in analysis and drug test standards. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a) Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 3, 2005. VerDate jul<14>2003 19:07 Mar 03, 2005 Jkt 205001 BILLING CODE 4410–09–P Drug Schedule Cathinone (1235) .......................... Methaqualone (2565) ................... Gamma-Hydroxybutyric Acid (2010). Lysergic acid diethylamide (7315) Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 3,4,5-Trimethoxyamphetamine (7390). 4-Bromo-2–5dimethoxyamphetamine (7391). 4-Methyl-2,5dimethoxyamphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 2,5-Dimethoxy-4ethylamphetamine (7399). 3,4-Methylenedioxyamphetamine (7400). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4-Methylenedioxymethamphetamine (7405). Psilocybin (7437) .......................... Psilocyn (7438) ............................. Acetyldihydrocodeine (9051) ........ Dihydromorphine (9145) ............... Heroin (9200) ............................... Tilidine (9750) ............................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Secobarbital (2315) ...................... PO 00000 Frm 00090 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I I I I I I I I I I II II II II Drug Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Methadone (9250) ........................ Dextropropoxphene (9273) .......... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Fentanyl (9801) ............................ Schedule II II II II II II II II II II II II II II II II The company plans to import small reference standard quantities of finished commercial product from its sister company in Switzerland for distribution to its customers for drug testing and pharmaceutical research and development. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file written comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than April 4, 2005. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–43746), all applicants for registration to import basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. E:\FR\FM\04MRN1.SGM 04MRN1

Agencies

[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Page 10680]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4222]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances Notice of Application

    Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 9, 2004, Lin Zhi 
International Inc., 687 North Pastoria Avenue, Sunnyvale, California 
94085, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of the 
basic classes of controlled substances listed in Schedule II.

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Oxycodone (9143)...........................  II
Hydrocodone (9193).........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for use in analysis and drug test standards.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a)
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than May 3, 2005.

    Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-4222 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P